BioSpace News Archive

Curasight A/S announces that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.

Abivax SA announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis, will be presented during the 19th Congress of the European Crohn’s and Colitis Organisation on February 21-24, 2024, in Stockholm, Sweden.

RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its fourth quarter 2023 financial results on Friday, March 1, 2024 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Oppenheimer & Co. Inc. (Oppenheimer) — a leading investment bank, wealth manager and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — today announced that its 34th Annual Healthcare Life Sciences Conference will be held February 13-14.

Enigma Biomedical USA announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer. Dr. Kolb’s passion for innovation and scientific rigor has driven his extensive career and broad recognition.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will provide a corporate update at the 17th Annual European Life Sciences CEO Forum to take place 28 - 29 of February, 2024 in Zurich, Switzerland.

Kraig Biocraft Laboratories, Inc., announces it has now taken possession of its new recombinant spider silk production center in Lam Dong Province, Vietnam.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for inhaled KB707 for the treatment of patients with solid tumors with pulmonary metastases that are relapsed or refractory to standard of care therapy.

LianBio announced that the Company’s Board of Directors had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares, each representing the right to receive one ordinary share, from the Nasdaq Global Market and deregistration under Section 12 of the Securities Exchange Act of 1934 and workforce reductions.